ArticleGastro hep advances2026
Competing Cardiometabolic Pathways of Obesity and Metabolic Dysfunction-associated Steatotic Liver Disease.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) progression is influenced by other metabolic disorders. However, quantitative evidence regarding disease pathway competition remains limited. In the current study, we utilized competing risk survival analysis to determine whether obesity-related MASLD development competes with hypertension and type 2 diabetes pathways. Methods: We conducted a 13-year (2007-2020) prospective cohort study involving 16,770 participants without MASLD, hypertension, or type 2 diabetes at baseline. Competing risk regression modeled the first occurrence of each disease during follow-up. Subdistribution hazard ratios (HRs) were estimated adjusting for age, sex, and baseline cardiometabolic parameters, with sensitivity analyses across body mass index (BMI) cutoffs and demographic subgroups. Results: Over a median follow-up of 8.3 years, high BMI (≥25 kg/m Conclusion: Individuals with a high BMI who developed MASLD exhibited a lower incidence of subsequent hypertension, suggesting apparent inverse associations that may reflect competing metabolic pathways. These findings suggest that obesity-related metabolic dysfunction may progress along distinct pathways-hepatic vs vascular-thereby supporting phenotype-specific risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.